[Value of erythrocyte adherence tests (SRCA tests) in the diagnosis and therapy of superficial bladder tumors].
Patients with superficial transitional cell carcinomas of the urinary bladder incorporating ABH-antigens will not develop infiltrating recurrent tumors in about 70%. The investigation of multiple-selected biopsies of the bladder mucosa in regard to ABH-antigenicity revealed an increasing deletion of ABH-antigens with the occurrence of dysplasias and in situ carcinomas. ABH-antigen negative tumors are significantly more often accompanied by dysplasia and carcinoma in situ (47%) than ABH-antigen positive tumors (23%). A chemoprophylactic treatment of patients with superficial bladder tumors after TUR was done prospectively. The prophylaxis with adriamycin decreased the percentage of progressive recurrent tumors from 70% (historical control) to 16% in the ABH-antigen negative tumor group.